A Multicenter Randomized Trial Comparing the Luteinizing Hormone-Releasing Hormone Analogue Goserelin Acetate Alone and with Flutamide in the Treatment of Advanced Prostate Cancer

@inproceedings{Tyrrell1991AMR,
  title={A Multicenter Randomized Trial Comparing the Luteinizing Hormone-Releasing Hormone Analogue Goserelin Acetate Alone and with Flutamide in the Treatment of Advanced Prostate Cancer},
  author={Christopher Tyrrell and J. Altwein and Friederike Klippel and Eberhard Varenhorst and Gerhard Lunglmayr and Francesco M Boccardo and Ian M. Holdaway and J.-M. Haefliger and J. P. Jordaan and Markku Sotarauta},
  year={1991}
}
AbstractA prospective randomized trial was conducted to compare the effects of the nonsteroidal antiandrogen flutamide (250mg. 3 times daily) plus the luteinizing hormone-releasing hormone analogue goserelin acetate (Zoladex) (3.6mg. subcutaneous depot injection every 28 days) with goserelin acetate alone in advanced prostatic carcinoma. A total of 571 eligible patients, of whom 57% had distant metastases, showed no difference in subjective or objective response rates, interval to progression… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 14 CITATIONS

Controversies in the management of advanced prostate cancer

  • British Journal of Cancer
  • 1999
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED